Table 3.
A brief summary of the major role of H2S and H2S-based therapy in pulmonary diseases.
| Pulmonary Diseases | Role of H2S (Enzymes Involved) | H2S-Based Therapy | Reference |
|---|---|---|---|
| Acute lung injury attributed to | |||
| - Sepsis/endotoxemia | Mainly detrimental (CSE/CBS) | Administration of PAG; Genetic silencing or deletion of CSE; Supply of NaHS or Lawesson’s reagent; Inhalation of H2S | [53,68,69,70,71,72,73,74,75,76,77,78,79,80] |
| - Acute pancreatitis | Mainly detrimental (CSE) | Administration of PAG; Supply of ACS15 or NaHS | [84,85,88,89] |
| - Burn/inhalation | Both detrimental and protective (CSE) | Administration of PAG or AOAA; Supply of AP39 or H2S parenteral formulation | [90,91,92] |
| Ventilation | Mainly protective | Inhalation of H2S; Supply of NaHS or Na2S | [94,95,96,98,99] |
| Pneumonia attributed to | |||
| - Mtb infection | Mainly detrimental (CSE/CBS) a | Administration of PAG; Genetic deletion of CSE or CBS | [102,103] |
| - RSV infection | Mainly protective (CSE/CBS) | Supply of GYY4137 | [104,105] |
| - SARS-CoV-2 infection | Both detrimental and protective a | NA | NA |
| Chronic obstructive pulmonary disease | Mainly protective (CSE/CBS) a | Supply of NaHS | [115,116,119] |
| Asthma | Mainly protective (CSE) a | Supply of NaHS | [130,131,132,133] |
| Lung cancer | Mainly detrimental (CSE/CBS) a | Administration of PAG or AOAA; Genetic silencing of CSE or CBS | [143,144,145] |
| Idiopathic pulmonary fibrosis | Mainly protective (CSE) | Supply of NaHS | [148,149] |
| Cystic fibrosis | Probably protective a | NA | NA |
| Sleep apnea syndrome | Mainly protective | Supply of NaHS | [158] |
| Pulmonary hypertension | Mainly protective (CSE) | Supply of NaHS | [164] |
Abbreviations: Not applicable (NA). a Human data are available.